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Abstract 
 Bone remodeling is a continuous process regulated by bone-forming cells, osteoblasts, 
and bone-degrading cells, osteoclasts.  Osteoclasts are derived from myeloid precursors. 
Increased differentiation and activation of osteoclasts offsets the balance of bone remodeling, 
causing the painful bone degradation associated with diseases such as osteoporosis, rheumatoid 
arthritis, and bone metastasis in cancer patients.  
 Osteoclast differentiation is brought about by an orchestrated transcription program in 
response to micro-environmental signaling. The full extent of this transcription factor network is 
not understood. Two transcription factors, MITF and PU.1, have been found to jointly regulate 
the transcription of many genes critical to the differentiation of myeloid precursor cells to 
osteoclasts. Through the use of chromatin immunoprecipitation coupled with high throughput 
sequencing (ChIP-Seq), we identified the genomic areas in developing osteoclasts enriched for 
MITF/PU.1 binding. Motif analysis revealed that 38% of these areas also included binding sites 
for the T-box transcription factor EOMES. Included in these sites were members of the complex 
transcription factor network governing osteoclast differentiation, such as NFATC1 and C-FOS.  
 To evaluate the physiological significance of transcription factor EOMES, we developed 
a myeloid specific knockout mouse model of EOMES. These mice had an osteopetrotic 
phenotype caused by reduced osteoclast differentiation and activity. These results were explained 
by a decrease in the expression of genes necessary for osteoclast differentiation, including 
Nfatc1. Therefore, we concluded that EOMES is another crucial transcription factor in early 
osteoclast differentiation. Understanding the intricate mechanisms controlling osteoclast 
differentiation is important for creating targets for therapeutic treatments of bone-related 
ailments. 
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I. Introduction 
a. Bone Structure and Remodeling 
 Bone is a living, growing tissue that provides structure and support to the human body. It 
is made up two layers: the hard outer layer, the cortical bone, and the spongy inner layer, the 
trabecular bone. These layers consist of organic collagen, a protein that provides the framework, 
and minerals that give the bone strength, such as hydroxyapatite (1).  Not only are bones 
necessary for locomotion, they also serve as a protective layer for vital organs. As one of the 
first-lines of defense against outside stresses, bones are constantly accumulating damage. 
 To maintain the integrity of the bone, a mechanism is in place to remove the damaged 
bone and replace it with new, healthy bone: bone remodeling. Bone remodeling is a continuous, 
lifelong process that responds to the persistent buildup of damage, and consists of two phases: 
resorption and ossification. Resorption involves osteoclasts, cells responsible for the degradation 
of the damaged bone. Osteoclasts originate from the hematopoietic stem cells, found in the bone 
marrow (2). Following resorption, osteoblasts, cells derived from the mesenchyme cell lineage, 
build new bone. The perfect balance of these two cells maintains the strength and mass of the 
bone.  
 
b. Bone-related Ailments 
 Imbalance of the osteoblast-osteoclast relationship is responsible for an assortment of 
bone-related ailments. Each year, approximately 1.5 million individuals suffer from bone 
fractures attributed to bone-related ailments (3). In the case of under activity of osteoclasts, the 
normal activity of osteoblasts trumps, causing the bones to become very dense. This condition is 
known as osteopetrosis. Osteopetrosis is a rare, autosomal recessive disorder. Symptoms of this 
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condition include fractures, low blood-cell production, and loss of cranial-nerve function. This 
could lead to blindness, deafness, and facial nerve paralysis (4).  
 More common, however is the hyperactivity of osteoclast (5). The most prevalent disease 
associated with hyperactivity of osteoclast is osteoporosis, a disease that leaves bones susceptible 
to damage due to the loss of bone mass and strength. Even mild stress to the bones can lead to a 
fracture. Osteoporosis causes shortened height, curvature to the back, reduced mobility, and pain 
in the bones (3). The disease is most common in post-menopausal women; estrogen decreases 
osteoclast production, and post-menopausal women experience a drastic drop in estrogen levels 
(6).  Although it is hard to diagnose before a fracture occurs, it is estimated that roughly 200 
million women worldwide suffer from osteoporosis (3). 
 Hyperactivity of osteoclasts is also present in rheumatoid arthritis. Rheumatoid arthritis is 
characterized by severe joint pain and swelling, stiffness and fatigue in the individual (7). It is an 
autoimmune disease, where immune cells become deregulated and attack the healthy cartilage of 
the joints (8). The bone destruction associated with rheumatoid arthritis is due to the 
overproduction and activation of osteoclasts. Rheumatoid arthritis affects approximately 1.3 
million Americans, seventy-five percent of which are female (5).  
 Along with these bone-related ailments, hyperactivity of osteoclasts plays a role in some 
cancers. Tumors can produce or induce signals that stimulate the production of osteoclasts (9). 
These degrade the bone, and supply cancer cells with a pathway for bone metastasis. Bone 
metastasis is very painful and can lead to bone fractures, adding to the long list of sufferings 
experienced by cancer patients.  
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c. Osteoclast Function and Differentiation 
 Osteoclasts’ function is carried out by three membrane domains: the sealing zone, the 
ruffled border, and the functional secretory domain. The sealing zone is the area of the cell that 
attaches to the bone matrix. The ruffled border provides hydrochloric acid and proteases to the 
resorption lacuna, an area between the border and the bone (10). Hydrochloric acid functions to 
degrade the minerals, such as crystalline hydroxyapatite, and the proteases degrade the collagen 
matrix of the bone. The resulting fragments are endocytosed, processed, and secreted by the 
functional secretory domain (10). Osteoclasts function at both the trabecular level and the 
cortical bone level, leading to an overall decrease in the volume of the bone. 
 Active, multinucleated osteoclasts are differentiated from myeloid stem cells via signals 
from two cytokines: macrophage colony-stimulating factor-1 (CSF-1) and receptor activator of 
nuclear factor (NF)-kB ligand (RANKL). CSF-1 is produced by osteoblasts and stromal cells, 
and plays a crucial role in the proliferation and survival of osteoclast precursors (11). After 
binding to the c-Fms receptor, a receptor of the tyrosine kinase family, the signal is relayed by 
the ERK1/2 and PI3K/Akt pathway. This induces the expression of genes crucial to promote the 
survival and differentiation of osteoclast precursors. Among these is the gene encoding the 
RANK receptor. The expression and transport of these receptors to the cell membrane prepares 
the osteoclast precursor for the subsequent signal (11). RANKL is also released by osteoblasts 
and stromal cells, and binds to the RANK receptors presented on the osteoclast precursors (5). 
This receptor-ligand complex recruits adaptor molecules to the cytoplasmic domain of RANK, 
which initiate the downstream regulation of osteoclast effector genes, effectively changing the 
physiology of the cell and producing multinucleated, active osteoclasts (5).  
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d. Osteoclast Transcription Factor Network 
 While these extracellular signals are necessary for the differentiation process, their cues 
must be propagated by the intracellular regulatory systems they activate. Signals by CSF-1 and 
RANKL lead to downstream activation of a complex transcription factors network. This intricate 
network contains factors that can have multiple functions in the differentiation process, such as 
regulate other transcription factors in the network, increase expression of osteoclast effector 
genes, and inhibit the expression of genes that would stall differentiation. Important members of 
the transcription factor network include a member of activator protein 1 (C-FOS), nuclear factor 
of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1), E26 oncogene homolog 
family transcription factor (PU.1), and micropthalmia-associated transcription factor (MITF) 
(5,12-­‐14).  
 These transcription factors regulate and maintain the expression of osteoclast effector 
genes that change the physiology of the myeloid precursor to active osteoclast. Some of the 
important genes upregulated following the activation of the network include tartrate-resistant 
acid-phosphatase (TRAP) gene (Acp5), which has important enzymatic function in resorption, 
cathepsin K (Ctsk), responsible for the degradation of collagen, osteoclast-associated receptor 
(Oscar), and calcitonin receptor (Calcr) (15-18), a receptor which binds calcitonin, a hormone 
important for calcium homeostasis. 
 The transcription factor network has captured the interest of many researchers. Members 
of the network play large roles in many other cell types, but in osteoclast differentiation, the 
interactions of all of these unique transcription factors are necessary to elicit an osteoclast-
specific response.  
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e. CFOS -/- mice and NFATC1 
 Along with its function in osteoclast differentiation, C-FOS is a marker of activated 
neurons, and its overexpression has been found in invasive mammary epithelial cells. C-FOS is a 
crucial member of osteoclast differentiation, as it is necessary for the expression of NFATC1 
(19). NFATC1 functions late in the transcription factor network. It is only activated following 
RANKL signaling, and plays a role in the maintenance of the osteoclast-effector genes. Apart 
from its role in osteoclast development, NFATC1 participates in immune responses.   
 Mice lacking C-FOS have an osteopetrotic phenotype and reduction in Nfatc1 expression. 
When NFATC1 is reintroduced into these mice, it restores the normal osteoclast production (19). 
C-FOS and NFATC1 have roles in different cell types, but C-FOS regulation of NFATC1 is 
necessary for osteoclast differentiation. The function of NFATC1 is vital for sustaining the active 
osteoclast physiology during its function.  
   
f. PU.1 conditional knockout and MITF mutant mouse models  
 The Ostrowski-Sharma laboratory has been especially interested in the relationship of 
MITF and PU.1, two functionally distinct transcription factors with an early, specific role in 
osteoclast differentiation.  
 PU.1 is present and active in all hematopoietic cells, making its expression necessary for 
the formation of macrophages, neutrophils, B-cells, and T-cells, in addition to osteoclasts (20). It 
contains an ETS binding domain of eighty-one amino acids, which binds to a highly conserved 
GGAA binding site on DNA. While PU.1 does not affect the commitment of hematopoietic cells 
to particular lineages, it is necessary for the process of differentiation to these lineages (20). 
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 MITF is a basic helix-loop-helix zipper transcription factor; its binding domain 
recognizes an E-box motif. After binding to this DNA site, it can control the regulation of 
lineage-specific genes by association with co-activators or co-repressors (21). Apart from its role 
in osteoclast differentiation, MITF functions in the development of mast cells, melanocytes, and 
optic pigment cells (21). In these cells, the role of MITF is extensive; it participates in the 
regulation of cell specification, proliferation, and differentiation.   
 Because of its role in all hematopoietic cells, complete knockout of PU.1 is embryonic 
lethal. To circumvent this obstacle, a myeloid-specific, inducible knockout of PU.1 was bred in 
the Ostrowski-Sharma laboratory. Following the conditional knockout of PU.1, the mice showed  
 
an osteopetrotic phenotype (unpublished: Carey, H. and Hildreth, Figure 1A, B). Rather than a 
deletion of MITF, MITF was mutated in the basic domain of the gene, making it incapable of 
binding to DNA. This model showed also showed an osteopetrotic phenotype (22).  
Figure 1: A. Micro CT image 
demonstrating osteopetrosis in 
PU.1 cKO mice B. 
Quantification of the 
percentage of bone volume to 
total volume.   C. The femur in 
Figure A stained for tartrate 
resistant acid phosphatase 
(TRAP), a common osteoclast 
marker of osteoclast, showing 
a decrease in functional 
osteoclast production in PU.1 
cKO mice.  D. Quantification 
of osteoclast    surface area to 
total bone surface area of PU.1 
cKO mice compared to 
controls.  
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 To explain the osteopetrotic phenotypes of these mice, the femurs were stained for the 
TRAP protein to quantify active osteoclast 
present on the bone.  In the mice lacking PU.1 
and functional MITF, there was decreased 
osteoclast present on bone surface and on the 
perimeter of the trabecular (22) (unpublished: 
Carey, H. and Hildreth, E., Figure 1C,D).  
 The overall cause of decreased 
osteoclast production was decreased expression 
of osteoclast effector genes in mice lacking PU.1 and functional MITF (Figure 2).  These results 
were found using primers of osteoclast-specific genes for quantitative real time PCR (qRT-PCR) 
of RNA isolated from mouse bone marrow-derived macrophages (BMMs) treated with CSF-1 
and RANKL.  
 
g. MITF and PU.1 Co-regulation  
 While the individual regulation of MITF and PU.1 is important in osteoclast 
differentiation, what has captured the attention of the Ostrowski-Sharma lab is the discovery that 
the two unique transcription factors physically interact to regulate many osteoclast-specific 
genes. Upon signaling from CSF-1 in bone marrow precursors, MITF is recruited to the promoter 
sites of osteoclast effector genes, stimulating the co-recruitment of PU.1 (23). After the 
combined signaling of RANKL, MITF is activated, and PU.1 and MITF jointly control the 
expression of the genes.  
Figure 2: qPCR Gene Expression analysis shows a dramatic 
decrease of osteoclast effector gene expression in PU.1 
knockout mice.  
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 In	  one study of MITF/PU.1 co-regulation, focused on Acp5, the gene encoding TRAP, 
MITF and PU.1 binding sites were found to be roughly 10bp apart in the gene (15). With the 
expression of only PU.1 or MITF in transfection assays, the activation of the Acp5 promoter 
increased 4-5 fold following RANKL signaling. But, with combined expression of MITF and 
PU.1, the activation increased 20-fold (15). Study of Oscar expression displayed a 4-5 fold 
increase in promoter activation with MITF-alone, but up to a 110 fold increase with the function 
of both transcription factors (17).  
 Along with genes that have a direct function in changing the physiology of the cell, MITF 
and PU.1 also regulate the function of important members of the transcription factor network, 
such as NFATC1 (24). It was shown that MITF/PU.1 binding at the Ctsk and Acp5 promoter 
stimulated their expression. Expression of these genes was necessary to recruit NFATC1 to its 
binding site on the Ctsk and Acp5 promoters, where it functions to maintain their expression 
(24).   
 
h. ChIP-seq of MITF and PU.1 
 The interaction between PU.1 
and MITF is one example of the 
unique regulation process of the 
osteoclast differentiation: functionally 
different transcription factors can elicit 
a very specific response. PU.1 is 
expressed in all hematopoietic cells; 
MITF is expressed in a multitude of 
B 
Figure 3: A. Overlapping MITF/PU.1ChIP-seq peaks in myeloid 
precursors and osteoclast. B. MITF and PU.1 co-bind to promoter 
regions of c-Fos and Nfatc1, members of the osteoclast 
transcription factor network.  
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cell types. But together, they allow for the expression of osteoclast-specific genes in committed 
myeloid precursors.  
 Because of the 
significance of this complex, the 
Ostrowski-Sharma laboratory 
conducted high throughput 
chromatin-immunoprecipitation 
sequencing (ChIP-seq) in both 
myeloid precursors and mature 
osteoclasts to gain insight into 
the magnitude of MITF/PU.1 co-
regulation. Overlapping the 
MITF/PU.1 ChIP-seq peaks 
revealed that the two 
transcription factors shared over 
five thousand binding sites in 
myeloid precursors, and over four 
thousand binding sites in mature 
osteoclasts (unpublished: Carey, H. and Sharma, S., Figure 3A). Of these sites of co-binding, 
over one thousand are involved with genes critical to osteoclast differentiation. Not only did 
these genes encode for proteins that elicit a direct change in cell type, they also included other 
transcription factors, such as C-FOS and NFATC1 (unpublished, Carey, H. and Sharma, S., 
Figure 3B).  
Figure 4: A. ChIP followed by qPCR confirmed MITF/PU.1 binding to peaks 
of after CSF-1 treatment that persisted following RANKL treatment. B. 
qPCR of RNA from BMMs treated with cytokines at different time points 
showed that knockout of PU.1 and mutations of MITF decreased the 
expression of Nfatc1 following RANKL treatment. PU.1 knockout shows a 
dramatic decrease in Nfatc1 expression.  
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 Many of these binding sites were confirmed using chromatin-immunoprecipitation 
followed by RT-PCR, including PU.1 and MITF binding at a site 5kbp from the promoter of 
Nfatc1 (Figure 4A). This binding suggests that PU.1 and MITF have important upstream 
regulatory functions in the transcription factor network.  
 The transcriptional regulation of Nfatc1 was confirmed with qRT-PCR analysis using 
RNA from BMMs treated with CSF-1 and RANKL from wildtype and knockout/mutant PU.1 
and MITF mice (Figure 4B). NFACT1 has a central role in maintaining osteoclast function, and 
has been shown to rescue normal phenotypes in osteopetrotic mice lacking other members of the 
transcription factor network. These results prove PU.1 and MITF are significant regulators of the 
transcription factor network.  
  
i. Motif Analysis reveals potential third partner  
 Because MITF and PU.1 interactions lead to 
extensive and specific regulation patterns, the Ostrowski-
Sharma lab wanted to look into possible co-factors that 
could assist MITF/PU.1 in their function. To search for 
the presence of other co-regulators, a motif analysis 
scored the DNA sites bound by the conserved GGAA 
binding site of PU.1 and E-box binding site of MITF. 
This revealed that almost 40% of these sites also 
contained the sequence for the T-box transcription factor 
binding site of Eomesodermin (EOMES) (unpublished: 
Carey, H. and Sharma, S., Figure 5). Included in these 
Figure 5: EOMES shares 40% of the 
sites co-bound by MITF and PU.1, 
important regulators of osteoclast 
differentiation.  
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sites bound by all three transcription factors were members of the transcription factor network, 
including C-FOS and NFATC1.  
 While EOMES normally functions during embryonic development, assisting in the 
formation of the mesoderm and central nervous system, this finding suggests that EOMES might 
also play a crucial role with MITF and PU.1 in the differentiation of osteoclast.  
 
II. Hypothesis 
EOMES is a novel transcription factor of osteoclast differentiation, co-regulating 
osteoclast-specific genes with MITF and PU.1.  
 Not only did ChIP-seq reveal the extent of the MITF/PU.1 co-regulation, it also exposed 
a potential third partner involved in the regulation of osteoclast-specific genes. Motif analysis of 
the peaks bound by MITF/PU.1 found that roughly thirty-eight percent of the shared sites also 
contained sequences for the binding of the T-box transcription factor, EOMES. EOMES has 
been previously studied for its role in mesoderm and nervous system formation during 
embryonic development, and its function in the differentiation of CD8+ T-Cells involved in 
immune responses (25,26).  But, since the EOMES binding sequence is prevalent in MITF/PU.1 
binding sites in osteoclasts, it may also have a role in osteoclast differentiation. 
  Included in these binding regions are members of the intricate transcription factor 
network of osteoclast differentiation, such as NFATC1 and C-FOS.  NFATC1 is necessary to 
produce and sustain the osteoclast cell type, and has been shown to rescue osteoclast production 
in mice lacking C-FOS. If MITF, PU.1, and EOMES interact to regulate the expression of 
Nfatc1, it would suggest that these three transcription factors act as early regulators of the 
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osteoclast transcription factor network, adding to the unique mechanism of osteoclast 
differentiation. 
 
Specific Aims:  
1. Confirm EOMES binding to sites co-bound by MITF and PU.1 
2. Analyze bone phenotype and osteoclast production in an EOMES conditional knockout 
mouse model 
3. Establish EOMES regulation in the transcription factor network 
4. Study EOMES role in transcription of osteoclast effector genes 
 
III. Methodology 
Mice Breeding and conditions:  All mice were maintained in the C57BL6/J background. Mice 
used were housed in a 12-hour light, 12-hour dark environment, with food, water, and care 
provided within the guidelines of the National Institute of Health and The Ohio State University 
Animal Care and Use Committee.  
 
Conditional knockdown of EOMES in myeloid cells:   
Mice with loxp sites surrounding the Eomes allele, 
Eomesfl/fl , were bred with Eomesfl/fl mice with a 
tamoxifen-inducible Cre recombinase under a c-FMS 
promoter, Eomesfl/fl ; Fms-ERtCre, to obtain  Eomesfl/fl 
(control) and Eomesfl/fl ; Fms-ERtCre (experimental) 





Eomesfl/fl	   Eomesfl/fl	  
(Control)	  





Figure 6: Mice breeding patterns to obtain the 
experimental and controls mouse models used in in 
vivo studies of osteoclast differentiation.  
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were injected with tamoxifen (50µg) 3 days after birth. When the mice were 8 days old, they 
were euthanized. Femurs and tibias were dissected and used for bone marrow flushing or subject 
to microCT scans to quantify bone defects.  
 
Mouse Genomic DNA Extraction and Preparation: Mouse-tails were clipped, and used as the 
source of DNA for genotyping. They were digested overnight at 55°C with 0.5mL TE-SDS 
(50mM Tris-Cl; pH 8.0, 100mM EDTA and 0.5% SDS) and 1µg/mL proteinase K. The DNA 
was centrifuged and supernatant transferred to a fresh tube containing 0.5mL isopropanol. This 
was centrifuged, and supernatant discarded. 70% ethanol was added, the mixture centrifuged, 
and supernatant discarded. 0.5mL Low EDTA was added to the DNA pellet and incubated for 1 
hour at 55°C. 
 
 Genotyping EOMES mouse models, Polymerase Chain Reaction (PCR): PCR amplication 
was used for genotyping of the wild-type and knockout mice. Approximately 150ng of extracted 
mouse DNA was added to a mixture of 1X Thermopol PCR Buffer, 0.2µM deoxy-nucleotide tri 
phosphates (dNTPs), 0.4µM of both forward and reverse primers for the EOMES allele 
(Invitrogen) (Table 1), and 2 units of Taq DNA polymerase for a total of 20µL.  
  
Genotype Forward Reverse 
Eomes (f/f, f/+, wt) 5’-AGATGGAAATTTGGGAAT-3’ 5’-GGCTACTACGGCCTGAAACT-3’ 
FTC 1 (+, -) 5’-TCGAAGCTTGCATGCCTGA-3’ 5’-TCTCTGCCCAGAGTCATCCT-3’ 
FTC 2 (+, -) 5’-TCATTCCAGAACCAGAGC-3’ 5’-GATCGTTGGGGAGCC-3’ 
Table 1: Primers used for genotyping Eomesfl/fl and FmsERtCre (FTC) mice 
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Genotyping EOMES mouse models, Agarose Gel Electrophoresis:  Agarose gels for 
genotyping were prepared by dissolving 2% concentration of agarose (Fisher Scientific) into 1X 
Tris-acetic acid-ethylenediaminotetraacetic acid, Na salt (EDTA) (TAE) buffer (40nM Tris-
acetate, 2mM Na2EDTA.2H2O; pH 8.0). 10% concentration of ethidium bromide was added to  
the mixture. 1X DNA loading dye (Thermoscientic) was added to the DNA samples and loaded 
into the wells of the agarose gel, submerged in 1x TAE Buffer, and separated at 100 volts.  
 
Cell Culture: Bone-marrow cells from femurs and tibias were extracted from adult mice and 
myeloid lineage was enriched by plating on non-adherent plastic plates in Dulbecco’s modified 
Eagle medium (DMEM, Gibco, Life Technologies, Carlsbad, CA) with 10% fetal bovine serum 
(Sigma-Aldrich, St. Louis, MO), 50 U/ml penicillin/streptomycin (Life Technologies, Carlsbad, 
CA) and 50ng/mL recombinant human CSF-1 (Peprotech, Rocky Hill, NJ) for three days. After 
three days in this culture, the non-adherent myeloid precursors were mechanically isolated and 
transferred to adherent tissue culture plates, 5 x 106 cells per 10cm plate. These cells were 
cultured in DMEM with 10% FBS, 50 U/mL Penicillin/Streptomycin, 50 ng/mL CSF-1 for five 
days. 100ng/mL recombinant human RANKL was added at day three (Peprotech, Rocky Hill, 
NJ). These cells were harvested at times indicated in the figures.  
 
Chromatin Immunoprecipitation (ChIP): BMMs from wild-type mice were plated  
 and treated with the differentiation-cytokines as indicated above. Before harvesting, the cells 
were treated with 1% concentration formaldehyde at 37°C for 10min. Nuclear extracts were 
sonicated by a Branson 250 digital sonicator (Branson Ultrasonics, Danbury, CT) to create DNA 
fragments of 200-600bp. ~5 x 105 cell equivalents of the fragmented DNA were treated with 
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Protein G-agarose beads. Roughly 10% of this DNA was set aside as an input control, the rest 
was treated with 5µg of EOMES antibody (Abcam). This was left overnight at 4°C. The Protein 
G-agarose was pulled down, washed extensively, and eluted twice with 250 L of elution buffer 
(0.1 M NaHCO3, 1% SDS). The cross-linking was reversed with 200mM NaCl and 20µg of 
RNase A (Sigma-Aldrich, St. Louis, MO) and left overnight. The isolated DNA was treated with 
Proteinase K (Roche, Basel, Switzerland) and purified with the Qiagen PCR purification kit 
(Invitrogen, Life Technologies, Carlsbad, CA). These samples were analyzed by qPCR on a 
StepOnePlus machine (Applied Biosystems, Life Technologies, Carlsbad, CA) using Taqman 
MasterMix (Roche, Basel, Switzerland) and Universal Probe Library Probes (Roche, Basel, 
Switzerland). The primer for Nfatc1 binding sites was designed using Universal Probe Library 
software (Roche, Basel, Switzerland) (Table 2). The threshold was adjusted according to the 





MicroCT Imaging of Mouse Skeletons: Bones of experimental and control mice were extracted 
from eight-day-old mice, fixed with 4% paraformaldehyde for 48hrs, and then stored in 70% 
ethanol until use.  Radiograph images were taken using a Siemens Inveon Preclinical CT scanner 
(Siemens AG, Munich, Germany) with settings at 100kV, 200MA, 1 second exposure, Bin 2, and 
a medium-high system magnification with a resolution of 0.019mm isotropic voxels. Image 
reconstruction was done using Cobra software (Exxim, Pleasanton, CA) and analyzed using 3D  
Forward 5’-TGCACTAGTTCCGCTTTCTTT-3’ 
Reverse 5’-CTGTCAGTATGGGGGATGCT-3’ 
Table 2: Primers designed for the EOMES, MITF, and PU.1 binding site located 5kbp from the Nfatc1 promoter region 
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bone morphology analysis software (Inveon Research Workplace 3D Image Software, Siemans 
PreClinical, Munich, Germany). Mineral bone density was measured using a ratio of mineralized 
bone to total bone volume (BV/TV). Trabecular density was measured in thickness of the 
trabecular (Tb.Th) (mm), trabecular number (Tb.No) (mm-1), and trabecular separation (Tb.Sp) 
(mm). 
 
Bone Histomorphometry: Femurs from eight day old mouse femurs were fixed in 3.7% 
paraformaldehyde, embedded in paraffin wax, cut into 4 µm sagittal sections, and stained for 
hematoxylin & eosin and tartrate-resistant acid phosphatase (TRAP) using a Leukocyte Acid 
Phosphate kit (Sigma-Aldrich, St. Louis, MO). These slides were scanned on an Aperia 
ScanScope XT (Vista, CA) and quantified using Aperio ImageScope software (Vista, CA). The 
osteoclasts present were measured using the ratio of osteoclast-covered surface to total bone 
surface (Oc.S/BS) and osteoclast number per millimeter of trabecular perimeter (Oc.No./Tb. 
pm). 
 
 RNA Extraction, cDNA Preparation and Quantitative Real-Time PCR (qRT-PCR): Total 
RNA was extracted from the RANKL/CSF1 treated BMMs using TRIzol method (Invitrogen), 
and purified according to the manufacturer’s protocol. 2µg of purified RNA was reverse-
transcribed using Superscript III reverse transcriptase (Invitrogen, Life Technologies, Carlsbad, 
CA) with random hexamer primers. Primers for the osteoclast-specific genes were designed 
using the Universal Probe Library software (Roche, Basel, Switzerland) (Table 3). qPCR was 
done using Taqman Master Mix (Roche, Basel, Switzerland) on a StepOnePlus machine 
(Applied Biosystems, Life Technologies, Carlsbad, CA). Relative expression of the target 
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mRNA compared to the ribosomal protein L4 internal control was calculated using a variation of 




Statistical Analysis: Unpaired student’s t-tests were done using Microsoft Excel for all 










Gene Left Right 
Acp5 5’-CGTCTCTGCACAGATTGCAT-3’ 5’-AAGCGCAAACGGTAGTAAGG-3’ 
Oscar 5’-TCTGCCCCCTATGTGCTATC-3’ 5’-TAGTCCAAGGAGCCAGAACC-3’ 
Ctsk 5’-CGAAAAGAGCCTAGCGAACA-3’ 5’-TGGGTAGCAGCAGAAACTTG-3’ 
Calcr 5’-GGTTCCTTCTCGTGAACAGGT-3’ 5’-AGAACTGGAGTTGGGCTCAC-3’ 
Table 3: Primers used for RT-PCR analysis 
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IV. Results 
EOMES co-binds to Nfact1 locus with MITF and PU.1: 
  Motif analysis revealed the binding sequence for 
EOMES at 40% of the sites shared by MITF and PU.1, 
suggesting that EOMES plays a role in osteoclast 
differentiation. Before any subsequent experiments of 
EOMES in osteoclast differentiation, the results shown by 
motif analysis needed to be confirmed. 
  Since it was revealed that an EOMES binding 
sequence is 5kbp from the promoter of Nfatc1, ChIP with 
EOMES antibodies was performed, using DNA from wild 
type BMMs treated with CSF-1 alone, or with RANKL for 
three days. To quantify the enrichment of EOMES, primers 
designed from the sites of MITF, PU.1 and EOMES binding sequences on Nfatc1 were used for 
qRT-PCR of the DNA bound by EOMES.  
 The results from these experiments verified EOMES binding near the promoter of Nfatc1 
during osteoclast differentiation: the binding was present following CSF-1 treatment and 
persisted after addition of RANKL signaling (Figure 7). These results mimic those found through 




Figure 7: ChIP with qPCR analysis 
confirmed EOMES binding to Nfatc1. 	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Mice with myeloid specific knockout of EOMES exhibit an osteopetrotic phenotype due to 
decreased osteoclast production: 
 An EOMES knockout mouse model was given to the Ostrowski laboratory to analyze the 
role of EOMES in osteoclast differentiation. Since complete Eomes allele deletion is embryonic 
lethal, we used a 
mouse model in 
which there is a 
conditional knockout 
of a “floxed” Eomes 




analysis of the femurs of 
EOMES WT and 
EOMES ΔMye/ΔMye mice 
determined the level of osteopetrosis, revealing an approximately 10% increase in mineral bone 
volume to total bone volume (BV/TV) due to increased trabecular number (Tb. No/mm) and 
thickness of the trabecular (Tb. Th.), and decreased space between trabecular bone (Tb. Sp.) in 
EOMES ΔMye/ΔMye mice (Figure 7 A,B). 
 To verify whether the mild osteopetrosis observed in EOMES ΔMye/ΔMye is osteoclast 
specific, the femur sections were stained for the osteoclast marker, TRAP. TRAP staining of the 
femurs showed a significant decrease in active osteoclasts in EOMES ΔMye/ΔMye  mice. (Figure 
Figure 8: A. Micro CT image of EOMES cKO mice show osteopetrotic phenotype, though 
milder than PU.1 cKO mice. B. Quantification of bone volume to total volume, and 
measurements of the trabecular bone. C. TRAP staining of A show decreased levels of 
osteoclast production. D. Quantification of osteoclast surface area:total bone surface area 
and osteoclast number: trabecular perimeter. (Carey,H. and Hildreth, E.) 
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7C). There was a decrease in the ratio of osteoclast-covered surface to total bone surface 
(Oc.S/BS) and osteoclast number per millimeter of trabecular perimeter (Oc.No./Tb. pm) (Figure 
7D).  
 
Myeloid-specific knockout of EOMES causes a decrease in Nfatc1 expression: 
  NFATC1 is important member of the osteoclast 
transcription network, implicated in the regulation of 
terminal osteoclast regulation. Since EOMES was found 
to be associated with MITF-PU.1 bound loci of Nfatc1 
enhancers,  the deregulation of the transcription factor 
network may be the cause of lowered osteoclast 
production seen in EOMES ΔMye/ΔMye mice. To validate 
this, we analyzed the effect of EOMES knockdown on 
Nfatc1 expression.  
 Total RNA was isolated from EOMES ΔMye/ΔMye 
and EOMES WT BMMs treated with and without 
RANKL. qRT-PC showed a two-fold Nfatc1 expression decrease in osteoclast from EOMES 
ΔMye/ΔMye mice following RANKL treatment (Figure 10), which contributes to a deregulated 
osteoclast transcription factor network. The timing of the expression regulation is consistent with 
PU.1 and MITF, proving that EOMES co-regulates upstream in the transcription factor network 
of osteoclast differentiation with MITF and PU.1.  
   
 
Figure 10: qPCR of EOMES ΔMye/ΔMye  
RNA showed a decrease in expression of 
Nfatc1 following RANKL treatment.  
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Knockout of EOMES in the myeloid compartment results in decreased expression of 
osteoclast-effector genes: 
 Since the transcription factor 
network of osteoclast differentiation 
becomes deregulated following myeloid 
cell knockout of EOMES, it should lead to 
a decrease in the genes controlled by the 
network. 
 BMMs of EOMES ΔMye/ΔMye and 
EOMES WT mice were harvested and 
treated with CSF-1 for two days, followed by CSF-1 and RANKL for three days. The RNA from 
these cells was isolated and qRT-PCR found the level of expression of osteoclast effector genes 
Acp5, Calcr, Ctsk, and Oscar.  
 When compared to osteoclasts from EOMES WT mice, osteoclasts from 
EOMESΔMye/ΔMye mice exhibited an approximately three-fold reduction in the expression of 
osteoclast marker genes (Figure 9). Each of these genes down regulated in cells lacking EOMES 
are necessary for the differentiation of myeloid cells to active osteoclasts.  This explains the 
decrease in active osteoclast in EOMES ΔMye/ΔMye mice and exhibits the regulatory function 
EOMES serves in osteoclast differentiation.  
 
V. Discussion and significance 
 The differentiation of osteoclast is unique from the differentiation processes of other cell 
types. Whereas differentiation to many cells types, such as muscle cells or melanocytes, requires 
Figure 9: qPCR data depicts decrease in osteoclast 
effector genes in EOMESΔMye/ΔMye mice. 
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simple mechanisms of transcriptional regulation, differentiation to active osteoclast requires a 
complex transcription factor network. Knocking out individual members of this network results 
in osteopetrotic phenotypes in mice, showing that the function of every member of this network 
is vital for normal differentiation. While many of members of the network have been discovered, 
the complete mechanism of this network is still largely unknown. In this study, we revealed 
EOMES as another member of the transcription factor network of osteoclast differentiation. 
 Discerning the factors and mechanisms involved in osteoclast differentiation is important 
to finding potential targets for effective and safe treatments of bone related ailments, such as 
osteoporosis and rheumatoid arthritis. While there are current treatment options for bone-related 
diseases, many of the treatments only succeed in slowing the progression of the disease, such as 
reducing fractures, or work to completely abrogate the differentiation of osteoclast (24). 
Although decreasing osteoclast production is successful in increasing bone mass, it completely 
ignores the importance of bone remodeling for maintaining healthy bones. Complete knowledge 
of osteoclast differentiation and function could reveal therapeutic targets for tailored treatments 
of excessive bone degradation that would allow for modulation of osteoclast activity, rather than 
complete ablation of osteoclast differentiation and function.   
 Knocking out individual members of the transcription factor network results in varying 
levels of osteopetrosis. A transcription factor in which osteopetrosis is mild after its 
deletion/mutation may prove to be a profound target for treatments. Results from this study 
shows promise for EOMES as a target. PU.1 and MITF have an early, established role in 
osteoclast differentiation. As a complex, they increase the production of osteoclast-specific genes 
dramatically. These factors would be unsuitable as a drug target, due to their large role in 
differentiation, and the role of PU.1 in many different myeloid lineages. This study showed that 
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EOMES co-regulates with MITF and PU.1, but the EOMES binding site is found in only 40% of 
the DNA sites bound by MITF and PU.1. While it does have a regulatory role in osteoclast 
differentiation, it is not as significant as its co-partners. There was only a ten percent increase in 
bone mass in EOMES knockout mice, as compared to a twenty percent increase in PU.1 
knockout mice. PU.1 knockout BMMs showed almost a complete loss of osteoclast-effector gene 
expression, whereas EOMES knockout BMMs exhibited a decrease in the expression of these 
genes, but the expression is not completely halted. 
 Because of the potential of EOMES, it is important to continue studies of the 
transcription factor in osteoclast differentiation. Co-immunoprecipitation with EOMES, MITF 
and PU.1 could give insight into whether the EOMES and MITF/PU.1 regulation occurs in the 
same complex, as well as reveal their respective domains of interaction. Additionally, ChIP-seq 
of EOMES would show the extent of EOMES regulation outside of co-regulation with MITF and 
PU.1. Not only could this expose separate functions of EOMES in osteoclast differentiation, but 
like the results found from MITF/PU.1 ChIP-seq, motif analysis of these peaks could expose 
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